Allergan ( AGN) revised fourth-quarter and 2005 numbers to include the benefit of a tax settlement.

The Irvine, Calif., healthcare company said it and the Internal Revenue Service entered into an agreement resolving certain tax disputes and permitting Allergan to release a valuation allowance taken in the fourth quarter of 2005 and certain tax contingencies established in prior periods. As a result of the settlement the company revised upwards by 13 cents a share its net earnings for the fourth-quarter and full-year 2005.

The company earned $140.1 million, or $1.03 a share, in the quarter. A month ago the company posted a presettlement quarterly profit of $122 million, or 90 cents a share.

Allergan had determined that it was required to record a valuation allowance against a deferred tax asset associated with the 2001 acquisition of Allergan Specialty Therapeutics. As a result of the settlement, Allergan determined that it is no longer required to record a valuation allowance against the deferred tax asset. The company shall release $5.9 million of accrued reserves for income tax contingencies related to the acquisition.
This story was created through a joint venture between and IRIS.